Copy Link Print Information

Nirmatrelvir

(Synonyms: PF-07321332)
111 Cited Publications
Kundenbewertung

Based on 111 publication(s) in Google Scholar

Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CLPRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit: 99.74%
  • CAS. Nr.: 2628280-40-8
  • Formel: C23H32F3N5O4
  • Molecular Weight:499.53
  • Speicherung:
    Powder   -20°C, 3 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Nirmatrelvir Chemical Structure
    Nirmatrelvir Chemical Structure
  • Experimental Validation Results for Nirmatrelvir
  • Experimental Validation Results for Nirmatrelvir
  • Experimental Validation Results for Nirmatrelvir
  • Experimental Validation Results for Nirmatrelvir
  • Experimental Validation Results for Nirmatrelvir
  • Experimental Validation Results for Nirmatrelvir
  • Experimental Validation Results for Nirmatrelvir
  • Experimental Validation Results for Nirmatrelvir
CAS. Nr.: 2628280-40-8
Größe
Preis
Verfügbarkeit
Menge
Amount: USD 0.00
Please select quantity
or
or

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Nirmatrelvir:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Finden Sie Ihren Händler vor Ort Your local distributor: Hycultec GmbHHycultec
  • Biologische Aktivität
  • Chemical Information
  • Lösungsmittel & Löslichkeit
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Nirmatrelvir

More
Customer Validation & Images
Bio/Physico-chemical AssayIn Vivo Efficacy StudyHistological Imaging/StainingIn Vivo ImagingCell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • Histological Imaging/Staining
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • Histological Imaging/Staining
  • Cell Proliferation/Viability Assay
  • Bio/Physico-chemical Assay
  • In Vivo Imaging
Keywords
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Einloggen
Registrieren
Sign in to MedChemExpress
Neuen Account Registrieren

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Nirmatrelvir Chemical Structure
    Nirmatrelvir Chemical Structure
    1/16
  • 1/16

    Nirmatrelvir purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Apr 3;16(1):2900. [Abstract]

    Customer Validation
     Mice were treated at 6 h, 24 h and 48 h with euthanasia performed at 72 h post-infection. WT 7-9 week-old mice were infected with SARS-CoV-2 P21 and treated with either vehicle, PLT (Paxlovid-like treatment: 56 mg/kg Nirmatrelvir, 19 mg/kg Ritonavir), or WEHI-P8 (100 mg/kg or 150 mg/kg). Three days post-infection, mice were monitored for d viral load and percentage change in body weight compared to initial body weight.

  • 1/16

    Nirmatrelvir purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Apr 3;16(1):2900. [Abstract]

    Customer Validation
     H&E staining showed that mice in the PLT treatment group (Paxlovid-like treatment: 56 mg/kg Nirmatrelvir, 19 mg/kg Ritonavir) exhibited mild to moderate multifocal inflammation, mainly confined to the peribronchial and perivascular areas of the lungs, with occasional alveolar collapse and mild hemorrhages.

  • 1/16

    Nirmatrelvir purchased from MedChemExpress. Usage Cited in: Nature. 2022 Jul;607(7917):119-127. [Abstract]

    Customer Validation
     Syrian hamsters were intranasally inoculated with 103 PFU of BA.2 (NCD1288). One day after infection, hamsters were treated with: 500 mg kg−1 molnupiravir, 1,000 mg kg−1 nirmatrelvir or 60 mg kg−1 S-217622 orally twice daily for 3 days. Methylcellulose served as a control for oral treatment. Eight hamsters per group were euthanized at 4 dpi for virus titration. Viral titres in the nasal turbinates and lungs were determined by plaque assay.

  • 1/16

    Nirmatrelvir purchased from MedChemExpress. Usage Cited in: Sci Immunol. 2023 Apr 14;8(82):eadf0348. [Abstract]

    Customer Validation
     DIO mice were infected with SARS-CoV-2 MA10 virus and treated with vehicle, Nirmatrelvir, or Nirmatrelvir plus MSDC. Host mortality was monitored and survival rate is shown.

  • 1/16

    Nirmatrelvir purchased from MedChemExpress. Usage Cited in: Sci Immunol. 2023 Apr 14;8(82):eadf0348. [Abstract]

    Customer Validation
     DIO mice were infected with SARS-CoV-2 MA10 virus and treated with vehicle, Nirmatrelvir, or Nirmatrelvir plus MSDC. H&E staining of lung section (n = 5) and quantification of pathological lesions at 21 d.p.i. Scale bar, 200 μm. HM, hyaline membranes.

  • 1/16

    Nirmatrelvir purchased from MedChemExpress. Usage Cited in: Vet Sci. 2023 Aug 9;10(8):513. [Abstract]

    Customer Validation
     The CC50, EC50, and SI for six compounds against FIPV. The half-maximal cytotoxic concentration (CC50) values are from four measurements of diluted drugs using MTT assay, in CRFK cells treated with drugs for 48 h. The half-maximal effective concentration (EC50) values are from six measurements of diluted drugs against FIPV replication in CRFK cells for 48 h. Based on the SI value (mean CC50)/(mean EC50), GS-441524 was found highly selective (SI 165.5) against FIPV among the drugs tested and showed high efficacy (EC50 1.6 µM) against FIPV with a less deleterious effect (CC50 260.0 µM) on the cells. Nirmatrelvir also showed promising efficacy (EC50 2.5 µM) and selectivity (SI 113.7) against FIPV. Ritonavir showed the highest toxicity level in the cells (CC50 39.9).

  • 1/16

    Nirmatrelvir purchased from MedChemExpress. Usage Cited in: N Engl J Med. 2023 Jan 5;388(1):89-91. [Abstract]

    Customer Validation
     Remdesivir, Molnupiravir, and Nirmatrelvir are efficacious against both BQ.1.1 and XBB in vitro.

  • 1/16

    Nirmatrelvir purchased from MedChemExpress. Usage Cited in: N Engl J Med. 2023 Jan 5;388(1):89-91. [Abstract]

    Customer Validation
     Representative echocardiographic images (M-mode) from sham, TAC and Tipifarnib (10 mg/kg body weight/three times a week, IP injection) treated TAC mouse heart at 8 weeks.

  • Nirmatrelvir